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Summary
Dementia is one of the most common neurological disorders in the elderly. Aging is associated
with a large increase in the prevalence and incidence of degenerative (Alzheimer’s disease) and
vascular dementia, leading to a devastating loss of independence. In view of increasing
longevity of populations worldwide, prevention and treatment of dementia has turned into a
major public health challenge. In the past decade, longitudinal studies have shown a close
association between high blood pressure in middle age, cognitive decline and dementia,
including Alzheimer’s disease, in the late life. Pathophysiologically, a summation of
cerebrovascular damage, white matter changes and pre-existing asymptomatic Alzheimer’s
brain lesions may lead to dementia, even when each type of lesion individually is not
sufficiently severe to cause it. Longitudinal studies assessing the beneficial role of
antihypertensive drugs on cognitive decline and dementia have produced promising results.
There are few randomised placebo controlled studies, although some of these have produced
positive results. Results of three recent meta-analyses are inconsistent, possibly due to
methodological issues. Further long-term randomised trials, designed especially to assess a link
between antihypertensive therapy and cognitive decline or dementia are therefore needed.
© 2008 Published by Elsevier Masson SAS.
Résumé
Les syndromes démentiels représentent la pathologie neurologique la plus fréquente des sujets
âgés. En effet, le vieillissement est associé à une augmentation importante de la prévalence et
de l’incidence des démences dégénératives (Maladie d’Alzheimer) et des démences
vasculaires, à l’origine d’une perte considérable d’autonomie. En raison de l’augmentation de
l’espérance de vie, la prévention et le traitement de démences sont devenus un problème
majeur de santé publique. Depuis les dix dernières années, plusieurs études longitudinales ont
mis en évidence une association solide entre l’hypertension artérielle, mesurée en milieu de
vie, et le déclin cognitif ou les démences, y compris maladie d’Alzheimer, à des âges plus
avancés. Sur le plan physiopathologique, la sommation de lésions cérébrales vasculaires et de
lésions dégénératives semblent contribuer à une expression anticipée d’une maladie
d’Alzheimer encore infraclinique faisant atteindre le seuil de démence plus précocement. Les
études observationnelles étudiant le bénéfice éventuel des traitements anti-hypertenseurs sur
le déclin cognitif et la démence ont donné des résultats prometteurs. Les essais randomisés
contre placebo restent peu nombreux mais certains d’entre eux mettent en évidence des
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résultats positifs (SYST-EUR, PROGRESS, HOPE). Les résultats des récentes méta-analyses
demeurent peu concluants en raison de l’hétérogénéité des études qu’elles incluent et de
problèmes méthodologiques. Il est donc nécessaire que d’autres essais randomisés soient
réalisés avec pour objectif premier d’évaluer l’impact des traitements antihypertenseurs sur le
déclin cognitif ou la démence.
© 2008 Published by Elsevier Masson SAS.
Introduction
Because of increasing life expectancy, the number of peo-
ple suffering from dementia in the world will increase from
24.3 million in 2000 to 81.1 million in 2040. Alzheimer’s
disease (AD) is the main form of dementia (70% of cases) in
western countries, the second leading cause (15% of cases)
being vascular dementia (VaD). AD is a neurodegenerative
disease associated with intraneuronal accumulation of
hyperphosphorylated tau protein, forming degenerative
neurofibrillary tangles and extracellular aggregation of Aβ.
This aggregation results from abnormal cleavage of protein
Aβ precursor (Amyloid Precursor Protein (APP)) by β- and
γ- secretases, resulting in a metabolic cascade responsible
for neuronal death and dementia. This major public health
problem makes research into risk factors for cognitive
decline and dementia a priority issue.
Many studies over the last decade have shown an associa-
tion between vascular risk factors and dementia, including
Alzheimer’s disease. Hypertension is a key vascular risk fac-
tor and many studies have assessed its links with cognitive
decline. The aim of this article is to present the major
published findings on this association and findings exami-
ning the effect of anti-hypertensive treatments on cogni-
tive function. 
Hypertension and cognitive decline
There is much and occasionally contradictory published
information about the links between hypertension and
cognitive function. The results depend on the methodology
used, such as the type of population studied (normotensive
or hypertensive), recruitment method (general population
or selected sample), methods by which blood pressure were
measured (several measurements, single measurement, in
the outpatient clinic or ambulatory), the presence or
absence of anti-hypertensive treatment, existence of other
cardiovascular risk factors and cognitive function assess-
ment method (preferentially exploring a cognitive domain
or globally exploring intellectual function).
Cross-sectional studies have shown positive [1] but also
negative correlations between hypertension and cognitive
disorders, whereas other studies have suggested a J curve
relationship between hypertension and cognitive decline.
By definition, these studies are extremely heterogeneous
and subject to multiple sources of methodological bias.
In this context, longitudinal studies appear to be far more
informative as they assess the effect of “chronic hyperten-
sion” on cognitive function. Most of these studies show a
positive relationship between midlife hypertension (around
50 years old) and cognitive decline (20-25 years later)
(table 1) or dementia (Alzheimer’s or vascular) (table 2) at
more advanced ages. The Framingham study [2] was one of
the first to find a positive correlation between the initial
blood pressure level (12 to 14 years before cognitive assess-
ment) and cognitive decline. Later work by Kilander et al [3],
in 999 men followed for 20 years showed that cognitive func-
tion assessed at the age of 70 years old was inversely related
to arterial blood pressure measured at the age of 50 year old.
In the EVA study [4], in older patients (average age = 65 years
old) the risk of cognitive decline was 2.8 times higher (95%
confidence Interval (CI)=1.6-5.0) in hypertensives after a
shorter follow up period (4 years). These results have been
confirmed in a far larger population (ARIC cohort; n=10,963)
with a follow-up period of 6 years old [5].
Hypertension does not only increase the risk of cognitive
decline but also the risk of dementia, regardless of type (vas-
cular or Alzheimer) (table 2). The “Honolulu-Asia Aging
Study” [6] found an increased risk of dementia (AD and VaD)
in 50-year-old hypertensive patients after follow-up for
25 years (n=3,703). Another study which included 1,449 peo-
ple showed that raised systolic blood pressure (SBP) to over
140 mmHg in midlife was associated with a significantly
increased risk of AD 21 years later [7]. The “Kungsholm pro-
ject” [8] suggested that pulse pressure plays a role in the
elderly (81 years old) in the development of dementia. In this
study, high SBP combined with a low diastolic blood pressure
(DBP) were responsible for the increased risk of AD. In the
same context the study found a positive association between
arterial stiffness measured by the pulse wave velocity and
cognitive disorders [9]. A 24% significant increase in risk of
dementia 30 years later was found in hypertensive patients
at inclusion in a recent retrospective study of 8,845 subjects
initially between 40 and 44 years old [10]. The study by
Skoog et al. [11], conducted in 1996, is particularly useful to
explain the occasionally contradictory results of the diffe-
rent other studies. This study demonstrated that blood pres-
sure at the age of 70 was higher in patients who developed
dementia 10-15 years later than in those who did not develop
dementia. Conversely, when the AD developed, a fall in
Abbreviations 
AD Alzheimer’s Disease
VaD Vascular Dementia 
SBP Systolic Blood Pressure
DBP Diastolic Blood Pressure 
RR Relative Risk 
HR Hazard Ratio
OR Odds Ratio
95% CI 95% Confidence Interval
Hypertension and cognition 183
blood pressure was seen, blood pressure levels in dementia
patients even becoming lower than in those who did not
develop dementia. Other studies have confirmed that arte-
rial blood pressure (BP) may be reduced in patients suffering
from AD [12]. Guo et al. [13] showed that BP was lower in
people over 75 years old suffering from AD than in those
without dementia, and that the reduction depended on the
severity of the dementia. The reasons for this fall in BP in
dementia is not entirely understood: comorbidities, reduced
physical activity or weight loss may contribute. In addition,
Table 1 Longitudinal studies. Association between blood pressure level and cognitive decline.
References N Age at 
inclusion 
(years)
Follow 
up 
Blood pressure threshold Association
Elias et al. 1993 
[2]
1702 55-88 12-14 BP (continuous variable) and 
chronic nature of hypertension
Positive
Launer et al. 
1995 [45]
3735 20 20-28 SBP≥160mmHg Positive 
OR (95% CI)=2.11 (1.22-3.66)
Starr et al. 1997 
[46]
603 >69 4 SBP≥160mmHg Positive
Kilander et al. 
1998 [3]
99 50 20 DBP divided into quintiles Positive
Swan et al. 1998 
[47]
717 45 25-30 SBP≥140mmHg, Positive.
Decline in memory functions and verbal 
learning 
Tzourio et al. 
1999 [4]
1172 59-71 4 SBP≥160/95mmHg Positive
OR (95% CI)=2.8 (1.6-5.0) 
OR (95% CI)=4.3 (2.1-8.8) in the absence 
of anti-hypertensive treatment
Knopman et al. 
2001[5]
10963 47-70 6 BP≥140/90mmHg or taking anti-
hypertensive treatment 
Positive
Reinprecht et al. 
2003 [48]
186 68 13 DBP (tertiles) Positive. A decline in DBP was inversely 
correlated with cognitive performances 
Piguet et al 
2003 [49]
377 ≥ 75 6 SBP/DBP>140/90mmHg Positive
Elias et al. 
2003 [50]
1423 55-88 4-6 SBP/DBP≥140/90mmHg Positive only in men
Waldstein et al. 
2005 [51]
847 70 6 SBP (continuous variable) Positive
Kuo et al. 
2005 [52]
2802 65-94 2 SBP/DBP≥140/90mmHg Positive
Waldstein et al. 
2008 [53]
1749 57 5 Pulse pressure Positive
Guo et al. 
1997 [54]
1736 75-101 3
• SBP≥180 mmHg vs 130-159 
mmHg with anti-hypertensive 
treatment
• SBP<130 mmHg vs 130-159 
mmHg without anti-
hypertensive treatment.
 J Curve 
– OR (95% CI)=1.6 (0.9-3.0)
– OR (95% CI)=1.9 (1.0-3.5)
Glynn et al. 
1999 [55]
3657 65-102 9 SBP<130mmHg or ≥160mmHg J. Curve 
Bohannon et al. 
2002 [56]
4136 65-105 3 SBP/DBP≥140/90mmHg J. Curve 
Tervo et al. 
2004 [57]
747 60-76 3 BP≥160/95mmHg Not significant
Solfrizzi et al 
2004 [58]
1445 65-54 3.5 Hypertension: past history, 
taking anti-hypertensive
treatment or BP≥140/90mmHg
Not significant
BP = blood pressure , SBP = systolic blood pressure, DBP = diastolic blood pressure, OR (95% CI) = odds ratio (95% confidence interval)
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the presence of degenerative Alzheimer’s disease lesions in
the prefrontal regions causing autonomic nervous system
dysfunction may contribute to the fall in BP [14].
Recent studies have also however found hypertension to
have a deleterious effect on cognitive decline in overt AD.
The study by Bellew et al. [15], on 700 patients suffering
from AD revealed an acceleration of cognitive decline in
hypertensive patients under 65 years old. This result was
confirmed in a second study conducted in 135 patients suf-
fering from AD, aged 84 years old, who were followed up for
an average of 3 years [16].
In conclusion, the links between BP and cognitive function
are more complex than a simple linear relationship. Chronic
hypertension predisposes to cognitive decline and to the
development of dementia, although a fall in BP can also been
when Alzheimer’s disease develops and progresses.
Anti-hypertensive treatments
and cognitive decline
The effect of anti-hypertensive treatments on preventing
cognitive decline and dementia has been assessed in obser-
vational studies and in a few randomised trials.
Results of the non-randomised trials on cognitive decline
are inconsistent. The anti-hypertensive agents were ini-
tially suspected to have an adverse effect on cognitive
function. Subsequently, most of the observational studies
suggested that anti-hypertensive therapies had a protective
effect on cognitive function. In the EVA cohort [4], the risk
of cognitive decline at 4 years was significantly lower in
treated, as compared to untreated hypertensives (RR (95% CI)
=1.9 (0.8-4.4) versus 4.3 (2.1-8.8)). Similarly, the results of
a study on 1617 elderly people followed up for 5 years
Table 2 Longitudinal studies. Association between blood pressure level and different types of dementia.
Dementia n Age at 
inclusion 
(years)
Follow up 
(years)
Blood pressure threshold Association 
Vascular dementia 
Yoshikate et al. 1995 [59] 828 74 7 BP≥160/95mmHg Positive
OR (95% CI) for a standard 
deviation of SBP=1.6 (1.2-2.2)
Skoog et al. 1996 [11] 382 70 9-15 SBP and DBP at inclusion Positive 
Launer et al. 2000 [6] 3 703 50 25 BP≥160/95mmHg Positive 
Yamada et al. 2003 [60] 1774 ≥65 25 SBP (continuous variable) Positive. OR for an increase in 
SBP of 10mmHg (95% CI)=1.33 
(1.14-1.56)
AD
Skoog et al. 1996 [11] 382 70 9-15 SBP and DBP at inclusion Positive 
Launer et al. 2000 [6] 3 703 50 25 BP≥160/95mmHg Positive 
OR (95% CI)=3.6 (1.4-9.6)
Kivipelto et al. 2001 [7] 1 449 53 21 SBP≥160mmHg Positive
OR (95% CI)=2.8 (1.1-7.2) 
Qiu et al. 2003 [8] 1 270 81 4.7 Pulse pressure Positive 
RR (95% CI)=1.4 (1.0-2.0)
Wu et al. 2003 [61] 602 >65 15 BP≥160/95mmHg OR(95% CI)=2.0 (1.1-3.5)
Freitag et al. 2006 [62] 2505 57 5.1 SBP≥140 mmHg Positive
HR (95% CI)=2.29 (1.23-1.45) 
Yamada et al. 2003 [60] 1774 ≥65 25 BP (continuous variable) No significant association 
Morris et al. 2001 [19] 634 >65 13 SBP≥160mmHg Negative
OR (95% CI)=0.30(0.1-0.9). 
Undifferentiated dementia 
Whitmer et al. 2005 [10] 8845 40 - 44 30 BP≥140/90mmHg Positive 
HR (95% CI)=1.24 (1.04-1.48)
Freitag et al. 2006 [62] 2505 57 5.1 SBP≥140mmHg Positive
HR (95% CI)=2.29 (1.23-4.25)
BP = blood pressure
SBP and DBP = systolic blood pressure and diastolic blood pressure
OR (95% CI) = odds ratio (95% confidence interval) 
RR (95% CI) = relative risk (95% confidence interval)
HR(95% CI) = hazard ratio (95% confidence interval)
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showed a 38% reduction in cognitive decline in treated
hypertensives compared to untreated patients (Odds Ratio
(OR) (95% CI) =0.62 (0.45-0.84)) [17]. 
Other studies have prospectively evaluated the links
between anti-hypertensive treatments and dementia
(table 3). Three of these studies found no significant asso-
ciation between taking an anti-hypertensive agent and AD
[18], [19], [20]. The Rotterdam study found that anti-
hypertensive treatments had a role in preventing VaD
although this association was not significant for AD [21].
Conversely, three other studies on large numbers of sub-
jects found a large reduction in the risk of dementia (30%)
[22] or AD (36 to 50% reduction) [23-24] that was associated
with anti-hypertensive treatment. The “Honolulu Asia
Aging” study highlighted the importance of the duration of
anti-hypertensive treatment: the reduction in the risk of
dementia increased with each additional year of anti-
hypertensive treatment [25]. Finally, a recent study sug-
gests that anti-hypertensive treatments can also slow
cognitive decline in patients suffering from AD [16].
In summary, several observational studies suggest that
anti-hypertensive treatments are beneficial in preventing
cognitive decline and dementia although this hypothesis
can only be confirmed by data from randomised, placebo-
controlled trials.
In this regard, six randomised, placebo-controlled trials
on large sample sizes have been conducted. The results of
these are shown in table 4.
Firstly, in the MRC trial [26], in a sub-group of 2,584
patients followed up for 54 months, no difference was
found in cognitive function between the treated group (Diu-
retics or  β-blockers) and the placebo group. The relatively
superficial neuropsychological assessment and short follow
up period however may not have allowed a difference to be
identified between the two groups.
In the SHEP trial [27], the incidence of dementia after a
5-year follow-up was not significantly different between
the group which received diuretics or β-blockers (1.6%) and
the placebo group (1.9%), although was slightly lower in the
treated group. The interpretation of the cognitive assess-
ments in this study may have been biased by missing neu-
ropsychological data for many patients [28].
The vascular dementia project included in SYST- EUR
trial [29] was the first to find a reduction in the incidence
of dementia associated with anti-hypertensive treatments.
This randomised trial included patients at 60 years old with
isolated systolic hypertension. One thousand two hundred
and thirty-eight patients received the active treatment
which consisted of a calcium blocker (nitrendipine) which
could be associated with an angiotensin converting enzyme
inhibitor (enalapril) and/or a diuretic (hydrochlorothia-
zide), and 1,180 patients received the placebo. Sixty per
cent of patients in the treatment group received the cal-
cium blocker alone. Average follow up was limited to
2 years as the study was stopped early because of the signi-
ficant benefit of the anti-hypertensive treatments in pre-
venting cerebrovascular accidents. The incidence of
dementia was significantly reduced by 50% in the treatment
group compared to the placebo group (3.7 cases per 1000
patient-years in the treatment group versus 7.7 cases per
1000 patients-years in the placebo group). These results
were observed for all types of dementia (VaD and AD).
At the end of the randomised, placebo-controlled phase,
all patients were given the option of starting or continuing
Table 3 Association between anti-hypertensives and dementia. 
Longitudinal studies.
References Number Age at 
inclusion 
(Years)
Follow up
(Years)
Type of dementia Association
Lindsay et al. 2002 [18] 6434 ≥65 5 AD Not significant 
RR (95% CI)=0.91 (0.64-1.30)
Morris et al. 2001 [19] 634 ≥65 4 AD No association 
Qiu et al. 2003 [24] 1270 75-101 6 AD
All types of dementia
Reduction 
RR (95% CI)=0.5 (0.5-0.9)
Reduction
RR (95% CI)=0.8 (0.6-1.0)
In’t Veld et al. 2001 [21] 7046 ≥55 2.2 All types of dementia
VaD
AD
Not significant
RR (95% CI)=0.76 (0.52-1.12)
Reduction
RR (95% CI)=0.30 (0.11-0.99)
Not significant
Yasar et al. 2005 [20] 1092 ≥60 11 AD Not significant
Katchaturian et al. 2006 
[23]
3308 ≥65 3 AD Reduction
RR (95% CI)=0.64 (0.41-0.98)
Guo et al. 1999 [22] 1810 ≥75 3 All types of dementia Reduction
RR(95% CI)=0.7 (0.6-1.0)
AD = Alzheimer’s disease
RR (95% CI) = relative risk (95% confidence interval)
VaD = vascular dementia 
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anti-hypertensive treatment for 2 years (SYST-EUR 2) [30].
The incidence of dementia in the patient group which had
been receiving anti-hypertensive treatment since randomi-
sation (4 years) was compared to the patient group only
taking anti-hypertensive treatment since the end of the
double blind period (2 years). At 4 years there was still a
difference in blood pressure between the group which ini-
tially received the anti-hypertensive treatment (n=1,485)
and the group which was initially given the placebo (n=1,417).
SBP was 7.0 mmHg higher and DBP 3.2 mmHg higher in the
placebo group. Sixty-four patients developed dementia.
Compared to the “control” group, long term anti-hyperten-
sive treatment reduced the incidence of dementia by 55%
(p<0.001) (from 7.4 to 3.3 cases per 1000 patient years).
The incidence of all types of dementia was reduced (AD,
VaD). After adjusting for age, sex, educational status and
blood pressure at inclusion, the relative Hazard ratio asso-
ciated with taking calcium blockers was 0.38 (95% CI=0.23-
0.64 ; p<0.001). These results indicate that treating 1,000
patients for 5 years could avoid 20 cases of dementia (95%
CI=7-33).
The principal objective of the randomised, placebo-con-
trolled PROGRESS trial (n=6,105) [31] was to establish
whether anti-hypertensive treatment (Perindopril ± Indapa-
mide) could reduce recurrence of strokes in patients who
had already suffered one. Its secondary objectives were to
examine the potential effect of anti-hypertensive treat-
ment on cognitive decline and dementia. The relative risk
of cognitive decline fell by 19% (95% CI=4 to 32%) in the
entire population and in 45% of patients who had recurrent
strokes (95% CI=21 to 61% ; p=0.001) after 4 years’ follow
up. The risk of dementia was reduced by 12% in the treat-
ment group in the entire population (95% CI=-8 to 28%) and
by 34% in patients who had recurrent strokes (95% CI=3 to
55%, p=0.03). This effect was seen in both hypertensive and
non-hypertensive patients. The significant reduction in the
risk of dementia (by 23%; 95% CI=0 to 41%) was seen on dual
therapy (SBP/DBP reduced by 12/5 mmHg) but not on
monotherapy (-8%; 95% CI=-48 to 21%), when the fall in
SBP/DBP was only 5/3 mmHg. 
The HOPE trial [32], which included 9,297 patients suffe-
ring from vascular diseases followed up for 4.5 years
showed a 41% reduction in cognitive decline associated with
stroke in the angiotensin converting enzyme inhibitor group
(ramipril) compared to the placebo group. The benefits
were particularly apparent for cognition and language
disorders. These results were found despite a relatively
modest reduction in blood pressure (3.8/2.8 mmHg). The
possible benefit of anti-hypertensive treatment on the
development of dementia was not studied in this work.
The SCOPE trial [33] assessed the effect of an angiotensin
2 receptor antagonist ± a diuretic on cognitive function in
4,964 hypertensive elderly subjects (70-89 years old). No
significant difference was found in cognitive function or
dementia after a follow-up period of 3.7 years. The diffe-
rence in blood pressure between the treatment group
patients and placebo group patients was small in this study
(3.2/1.6 mmHg). For ethical reasons, most patients in the
Table 4 Effects of anti-hypertensive treatments on cognitive decline or dementia in randomised, placebo-controlled
trials.
Studies N ΔSBP/DBP
(Treatment –
placebo)
Anti-hypertensive 
treatments
Follow-up Results 
MRC [26] 2584 -15.8/5 mmHg - blockers or Diuretics 54 
months 
No significant effect on cognitive function 
SHEP [27] 4736 -12/4 mmHg - blockers±Diuretics 4.5 years 16% reduction in dementia 
(not significant)
SYST-EUR [29] 2418 -8.3/3.8 mmHg CCB±ACEI±Diuretics 2 years 50% reduction in dementia 
(0 to 76%)
SYST-EUR 2 [30] 
(Open trial)
2902 -7/3.2 mmHg CCB±ACEI±Diuretics
± others
4 years 55% reduction in dementia 
(24 to 73%)
PROGRESS [31] 6105 -9/4 mmHg ACEI± Diuretics 4 years 19% reduction in cognitive decline 
(4 to 32%)
 23% reduction in dementia on dual 
therapy (0 to 41%)
34% reduction in dementia with recurrent 
strokes (3 to 55%)
HOPE [32] 9297 -3.8/2.8 mmHg ACEI 4.5 years 41% reduction in cognitive decline 
associated with stroke (6 to 63%)
SCOPE [33] 4964 -3.2/1.6 mmHg ARA2±Diuretics 3.7 years 7% reduction in dementia 
(not significant)
Reduction in cognitive decline in patients 
with mild cognitive impairment (p=0.04)
CCB = calcium channel blockers 
ACE I = angiotensin converting enzyme inhibitors 
ARA2 = angiotensin 2 receptor antagonists
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placebo group in reality were given anti-hypertensive treat-
ment (other than candesartan). The absence of treatment
benefit may be explained by this small difference in reduc-
tion in blood pressure and the relatively short follow up
period. The results however highlighted the prevention of
cognitive decline in patients who had already a mild cogni-
tive impairment at inclusion (MMSE between 24 and 28), with
the active treatment compared to the control group [34]. 
Recent meta-analyses which have included these rando-
mised trials have provided an overview of the role of anti-
hypertensive treatments on cognitive function.
The 2006 Cochrane review [35] concluded that reducing
blood pressure produced an 11% fall in the relative risk of
developing dementia in patients without cerebrovascular
abnormalities, although that this effect was not statisti-
cally significant (OR=0.89 ; 95% CI=0.69-1.16). This review
included randomised, placebo-controlled trials lasting more
than 6 months, the minimum time required to be able to
observe an effect on cognitive function. Three randomised,
placebo-controlled trials were included: SCOPE, SHEP and
SYST-EUR, representing a total of 12,091 patients. The ana-
lysis was conducted from aggregate data and not individual
patient data. In addition, the PROGRESS trial was not inclu-
ded in this meta-analysis, which may have contributed to
the result obtained not being significant.
A second meta-analysis assessed the effect of anti-hyper-
tensive treatments in patients suffering from cardiovascular
diseases. This showed a borderline-significant trend fall (by
20%) in dementia (OR (95% CI) =0.80 (0.63-1.02) [36]. The
PROGRESS, SCOPE, SHEP and SYST-EUR trials were included
in this meta analysis. The HOPE and MRC trial results were
not included because of missing data. The failure to obtain a
significant result may be explained by lack of power to
detect treatment effects due to the relatively short follow-
up time for this type of disease. Here again, the analysis was
based on studying aggregate data which are potentially less
relevant than individual patient data. 
The meta-analysis by Bierkenhager et al. [14] incorpora-
ted the difference in fall in blood pressure fall obtained
between groups (treatment versus control) in the different
trials. With a fall in SBP >5 mmHg, i.e. after excluding the
SCOPE and PROGRESS-monotherapy trials, the analysis
found a 25% significant reduction in dementia OR (95%
CI=0.75 (0.60-094)). The authors stressed the potentially
more important effect of the calcium blockers (SYST-EUR 1
and 2) compared to renin-angiotensin system blockers
(SCOPE, PROGRESS-monotherapy).
Finally, the meta-analysis by Birns et al. [37] assessed
the effect of anti-hypertensive treatments on different
cognitive function. Sixteen randomised trials, i.e. 19,501
subjects were included in this meta-analysis. Eight were
randomised, placebo-controlled trials and eight others
compared the effect of different anti-hypertensive treat-
ments. In 4 of these trials, the cognitive assessment was
performed using the Mini Mental State Examination (MMSE),
a test which assesses global cognitive function. These
showed a modest but significant improvement in MMSE
(Weighted Mean Difference (WMD) =0.19 ; 95% CI=0.19-
0.19) with anti-hypertensive treatment. In five of the trials,
a logic memory test was conducted. Reducing blood pres-
sure appeared to benefit both immediate memory
(WMD=0.62 ; 95% CI=0.21-1.02) and delayed memory
(WMD=0.67 ; 95% CI=0.23-1.11) but not on executive func-
tions. Anti-hypertensive treatments appear to have a hete-
rogeneous effect on the different cognitive functions. Lar-
ger scale, randomised studies are needed to confirm these
results, using precise neuropsychological tests able to
assess all types of cognitive function (immediate and defer-
red memory, language, judgement, attention, executive
functions etc.).
The results of these meta-analyses are discordant and do
not allow a formal conclusion to be drawn. Additional ran-
domised studies are needed with the primary objective of
assessing the relationship between anti-hypertensive treat-
ments and cognitive function or dementia.
Pathophysiological mechanisms 
Several pathophysiological mechanisms may explain the asso-
ciation between hypertension, cognitive disorders and demen-
tia. The histo-pathological studies show a frequent association
between vascular lesions and neuropathological lesions of AD.
In 25 to 50% of cases, histological examination of dementia
patients reveals the co-existence of cerebrovascular lesions
and histological lesions of Alzheimer’s disease [38]. 
Hypertension gives rise to vascular modifications which
affect blood flow and cerebral metabolism. Cognitive disor-
ders may therefore be associated with the presence of focal
ischaemic lesions (infarction, lacunae) and/or chronic
ischaemia of the white matter due to small cerebral artery
disease (arteriosclerosis, lipohyalinosis). It is the summation
of vascular and degenerative lesions which may contribute to
the early expression of still sub-clinical Alzheimer’s disease
reaching the dementia threshold earlier [39] (figure 1).
Several studies have found a significant association
between hypertension, the presence of white matter
lesions and cognitive disorders [40]. Progression of white
matter lesions has also been shown to be associated with
the development of cognitive decline. A longitudinal study
found an increase in risk of AD which was dependent on the
volume and extent of peri ventricular white matter lesions
[41]. Similarly, a very recent study has shown that white
matter lesions are significantly associated with cognitive
decline in patients already suffering from moderate
memory disorders (Mean follow-up period=3.8±1.6 years)
[42]. Interestingly, in the PROGRESS trial, anti-hypertensive
Figure 1. Contribution of vascular lesions and degenerative
lesions to clinical expression of dementia. 
From Pasquier et al. [39] the additive diseases hypothesis.
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treatment reduced the progression of white matter lesions
[43], suggesting a mechanism of action for this type of
treatment in reducing cognitive decline.
Disorders of cerebral microcirculation and endothelial
function may also be responsible for cognitive disorders in
hypertensive patients. Hypertension is associated with chan-
ges in cerebral arterials and capillaries. Similarly AD is
accompanied by cerebral microvascular lesions (amyloid
angiopathy, adverse changes in smooth muscle and endothe-
lial cells and in the basal membrane, hyalinosis and fibrosis)
[44]. All of these vascular changes may damage the blood-
brain barrier leading to increase in vascular permeability and
extravasation of proteins into the cerebral parenchyma,
resulting in accumulation of Aβ proteins. In addition, β-amy-
loid proteins can also promote excessive production of free
radicals in endothelial cells, which are responsible for neuro-
nal cell death. These factors suggest that oxidative stress
may be involved in the vascular disorders and AD.
Finally, episodes of hypotension, hypoperfusion and
hypoxia which are seen in hypertensive patients may contri-
bute to the cognitive deficit in AD through a reduction in
cerebral blood flow causing neuronal ischaemia in the most
vulnerable regions of the brain.
Conclusion
There are solid epidemiological arguments to support an
association between hypertension, particularly in midlife,
and the development of cognitive disorders and dementia,
including AD. Conversely, once the disease has become
apparent a fall in blood pressure may be seen. The patho-
physiological mechanisms underpinning this link have not
yet been clearly established although the summation of
cerebrovascular and degenerative lesions appears to contri-
bute to early expression of as yet sub-clinical Alzheimer’s
disease reaching the dementia threshold earlier. Longitudi-
nal studies examining the possible benefit of anti-hyperten-
sive treatments on cognitive decline have produced promi-
sing results. There are only a few randomised, placebo-
controlled trials, some of which show positive results (SYST-
EUR, PROGRESS, HOPE). The results of recent meta-analy-
ses however remain relatively inconclusive because of the
heterogeneous nature of the studies which they have inclu-
ded and because of methodological difficulties. Other ran-
domised trials with the primary objective of assessing the
impact of anti-hypertensive treatments on cognitive
decline or dementia are therefore required, particularly in
patient populations at high risk of cognitive decline (very
elderly patients or patients who already have moderate
cognitive disorders) and their results incorporated into new
meta-analyses allowing individual data to be studied.
Conflict of interest: none declared.
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